Becker's Healthcare March 25, 2024
Medicare total spending hit $5.7 billion in 2022 for GLP-1 drugs such as Ozempic, Wegovy and Mounjaro, up from $57 million in 2018, according to a March 22 KFF analysis.
GLP-1 drugs were originally developed to treat Type 2 diabetes but have since gained popularity as medications used to tackle obesity.
While Medicare is not allowed under existing law to cover the drugs for weight loss, Medicare Part D plans can cover them for other medically accepted indications, such as reducing cardiovascular risk, according to a recent...